兰索拉唑联合铝碳酸镁治疗幽门螺旋杆菌相关性胃溃疡临床疗效观察

Clinical Effect Observation on Lansoprazole Combined Hydrotalcite in Treatment of Helicobacter Pylori Related Gastric Ulcer

目的探讨铝碳酸镁联合兰索拉唑治疗幽门螺旋杆菌相关性胃溃疡的临床疗效。方法选取我院2013年7月~2014年7月收治的78例幽门螺旋杆菌相关性胃溃疡患者,随机将患者分为对照组和观察组,每组39例,入院后,两组患者采取三联疗法根除治疗幽门螺旋杆菌,对照组患者采用兰索拉唑治疗,观察组在对照组的基础上采用铝碳酸镁治疗,8周后,观察患者的临床疗效。结果观察组患者幽门螺旋杆菌的根除率为89.7%,治疗的总有效率为94.8%,对照组患者幽门螺旋杆菌的根除率为66.7%,治疗的总有效率为74.3%,两组患者数据对比差异具有统计学意义,P〈0.05。同时,两组患者术后产生不良反应情况对比差异无统计学意义,P〉0.05。结论采用铝碳酸镁联合兰索拉唑治疗幽门螺旋杆菌相关性胃溃疡,能够有效根除幽门螺旋杆菌,提高溃疡的愈合质量。

Objective To evaluate the clinical efficacy of lansoprazole combined with hydrotalcite in treatment of helicobacter pylori associated with gastric ulcer. Methods Selected 78 cases of helicobacter pylori gastric ulcer patients from our hospital in July 2013 to July 2014. The patients were randomly divided into control group and observation group, 39 cases in each group. After admission,the patients in the two groups took triple therapy eradication therapy for helicobacter pylori（HP）and in the control group was treated with lansoprazole treatment,the observation group based on the control group for hydrotalcite treatment. After 8 weeks,observed the patient＇s clinical curative effect. Results The eradication rate of helicobacter pylori in the observation group was 89.7%,the total effective rate was 94.8%,and the total effective rate was in the control group were 66.7% and 74.3%,and the difference was statistically significant between the two groups,P 0.05. At the same time, there was no significant difference between the two groups of patients with adverse reactions,P 0.05. Conclusion The hydrotalcite combined lansoprazole in treatment of helicobacter pylori associated gastric ulcer, can effectively eradicate helicobacter pylori,improve ulcer healing quality.